

Please type a plus sign (+) inside this box → ☐ +

PTO/SB/21 (6-98)

Approved through 09/30/2000. OBM 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/834,596
Filing Date	13 April 2001
First Named Inventor	WATANABE
Group Art Unit	1614
Examiner Name	Not Assigned
Attorney Docket Number	PHARM1

Total Number of Pages in This Submission

AUG 21 2001
RECEIVED
1614 #4
1600/2900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request; 1 mo. <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) 4 sheets <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): Return Receipt Postcard PTO-1449 Copies of References Cited
<input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. § 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Jacqueline Haley, Registration No. 41,457
Signature	
Date	15 August 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 15 August 2001

Typed or printed name	Jacqueline Haley		
Signature		Date	August 15, 2001

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Patent
Customer No.: 006980
Docket No.: PHARM1

TECH CENTER 1600/2900

AUG 21 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of)	
)	
WATANABE, K., et al.)	Group Art Unit: 1614
)	
Serial No.: 09/834,596)	Examiner: Not Assigned
)	
Filed: 13 April 2001)	
)	
For: 3' OR 2'-HYDROXYMEHTYL)	
SUBSTITUTED NUCLEOSIDE)	
DERIVATIVES FOR THE)	
TREATMENT OF HEPATITIS)	
VIRUS INFECTIONS)	

INFORMATION DISCLOSURE STATEMENT

Honorable Assistant Commissioner of
Patents
Washington, D.C. 20231

Atlanta, Georgia 30308-2216


Dear Sir:

In accordance with the continuing duty under 37 C.F.R. §1.56 to disclose to the United States Patent and Trademark Office any information that may be material to the patentability of the above-identified invention, enclosed please find form PTO 1449 listing references presently known to Applicants relating to the above-identified application. Also enclosed are copies of the cited references. The submission of this information shall not be deemed an admission that this information is necessarily material to the patentability of the above-identified application.

This information disclosure statement is being submitted prior to the mailing of a first Office Action on the merits. Therefore, Applicants believe that no fee is due under 37 C.F.R. §1.17.

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment to PTO Deposit Account No. 20-1507.


Respectfully submitted,


Jacqueline Haley
Registration No. 41,457

I hereby certify that this correspondence is being deposited with the United States Postal Service with appropriate first class postage in an envelope addressed to: Honorable Assistant Commissioner of Patents, Washington, D.C. 20231 on 8-15-01

Jacqueline Haley, Reg. No. 41,457

Name of Registered Representative


Signature

8-15-01

Date

TROUTMAN SANDERS LLP
Bank of America Plaza, Suite 5200
600 Peachtree Street, N.E.
Atlanta, Georgia 30308-2216
404.885-3561

OFFICE
 AUG 17 2001
 PATENT & TRADEMARK OFFICE

Approved for use through 10/31/99. OBM 0651-0031
 Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/834,596
			Filing Date	13 April 2001
			First Named Inventor	Watanabe, K.
			Group Art Unit	1614
			Examiner Name	Not Assigned
			Attorney Docket Number	PHARM1
Sheet	1	of	3	


[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the twoletter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OBM 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED
AUG 21 2001

Substitute for form 1449B/PTO		Application Number	09/834,596
INFORMATION DISCLOSURE		Filing Date	04/13/01
STATEMENT BY APPLICANT		First Named Inventor	WATANABE
(use as many sheets as necessary)		Group Art Unit	1614
Sheet 2 of 3		Examiner Name	Not Assigned
		Attorney Docket Number	PHARM1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Code No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, paper(s), volume-issue number(s), publisher, city and/or county where published.	T ²
		Fedorov, I., et al., XIII International Round Table: Nucleosides, Nucleotides and Their Biological Applications. Montpellier, France, September 6-10, 1998. Poster 35.	
		Kato, K., et al., XIII International Round Table: Nucleosides, Nucleotides and Their Biological Applications. Montpellier, France, September 6-10, 1998. Poster 49.	
		Svansson, L., et al., J. Org. Chem., 1991, 56: 2993-97	
		Wengel, J., et al., Bioorganic & Medicinal Chemistry, vol. 3, No. 9, pp. 1223-29, 1995.	
		Lin, T., et al., J. Med. Chem., 1993, 36:353-62	
		Gauvry, N., et al., Tetrahedron 55 (1999) 1321-28.	
		Sterzynski, R., et al., Nucleosides & Nucleotides, 10(1-3), 291-94 (1991)	
		Lee-Ruff, E., et al., J. Med. Chem., 1996, 39:5276-80	
		Bamford, M., et al., J. Med. Chem., 1990, 33:2494-2501	
		Tino, J., J. Med. Chem, 1993, 36:1221-29	
		Brown, B., J. Org. Chem., 1998, 63:8012-18	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the twoletter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+



PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Application Number	09/834,596
INFORMATION DISCLOSURE		Filing Date	04/13/01
STATEMENT BY APPLICANT		First Named Inventor	WATANABE
(use as many sheets as necessary)		Group Art Unit	1614
		Examiner Name	Not Assigned
		Attorney Docket Number	PHARM1
Sheet	3	of	3

RECEIVED
AUG 21 2001
FEDERAL CENTER 1600/2900

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Code No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, paper(s), volume-issue number(s), publisher, city and/or county where published.	T ²
		Pudlo, J., Nucleosides & Nucleotides, 11(2-4), 279-93 (1992)	
		Fiandor, J., et al., Nucleosides & Nucleotides, 8(5&6), 1107-8 (1989)	
		Jeong, L., et al., Nucleosides & Nucleotides, 16(7-9), 1059-62 (1997)	
		Jorgensen, P., et al., Nucleosides & Nucleotides, 16(7-9), 1063-66 (1997)	
		Frieden, M., et al., J. Chem. Soc. Perkin Trans I, 1998, 2827-32	
		Slusarchyk, W., J. Med. Chem., 1992, 35:1799-1806	
		Bisacchi, G., et al., J. Med. Chem., 1991, 34:1415-21	
		Qiu, Y., et al., J. Med. Chem., 1998, 41:10-23	
		Sekiyama, T., J. Med. Chem., 1998, 41:1284-98	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the twoletter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.